Catalyst Pharmaceuticals(CPRX) - 2023 Q1 - Quarterly Report

Catalyst's New Drug Application for FIRDAPSE ®(amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS) was approved in 2018 by the U.S. Food & Drug Administration (FDA), and FIRDAPSE ®is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, approved the use of FIRDAPSE ®for the treatment of adult patients in Canada with LEMS in 2020 and FIRDAPSE ®is commercially a ...